Patent intelligence · US
US 11098025
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
Patent details — US 11098025
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 24, 2021
- Expiration
- Aug 19, 2041
- Applicant
- Montelino Therapeutics Inc.
- Claims
- 20
- CPC classes
- A61K, A61K45/06, A61P, A61P13/08
Quick answer
US 11098025 (Bi-functional compounds and methods for targeted ubiquitination of androgen receptor) is held by Montelino Therapeutics Inc.. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Montelino Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K45/06, A61P, A61P13/08, A61P35/00, A61P35/04
More from Montelino Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 11098025?
US 11098025 (Bi-functional compounds and methods for targeted ubiquitination of androgen receptor) is held by Montelino Therapeutics Inc.. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11098025?
Montelino Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 11098025 expire?
Our index shows an expiration date of Aug 19, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.